摘要
目的研究头孢呋辛、头孢噻肟、头胞他啶治疗新生儿败血症的药物经济学效果。方法用决策树分析方法进行3种头孢菌素类抗生素治疗新生儿败血症的成本—效用分析,以多属性效用理论(MAUT)考察有效率、治疗费用、不良反应发生率及住院天数等因素对新生儿败血症抗菌药物选择的影响。结果决策树分析显示3种头孢菌素类抗生素治疗新生儿败血症均取得较好疗效,其期望成本分别为2490、2586、2270元;MAUT分析显示头孢他啶组优于其它2组药物。结论从药物经济学角度来看,头孢他啶组治疗新生儿败血症优于头孢呋辛组与头孢噻肟组。
Objective To study pharmacoeconomics using decision analysis of used 3 kinds of cephalosporins in the treatment of neonatal septicemia. Methods The data of 94 neonatal septicemia patients（37 cefuroxime recipients, 34 cefotaxime recipients and 23 ceftazidime recipients） were evaluated. Decision analysis was used to evaluate the cost-effectiveness ,and multi- attribute utility theory（MAUT） was used to incorporate a humanistic evaluation of effectiveness, safety , cost and hospital stay. Results The decision tree analysis revealed that the predicted costs of 3 eephalosporinses on the treatment of neonatal septicemia were RMB 2490,2586,2270 yuans respectively. The MAUT analysis showed that cefiazidime was the optimum medicine among the 3 cephalosporinses. Conclusion In terms of pharmacoeconomics,ceftazidime groups were the optimum medicine among the 3 cephalosporinses groups in the theatment of neonatal septicemia.
出处
《中国医院统计》
2006年第3期208-211,共4页
Chinese Journal of Hospital Statistics
